Speakers & Program

2025 Meeting Program OverviewView Daily Sessions

The 2025 CIMT Annual Meeting will again feature the latest breakthroughs in translational cancer immunotherapy research, with a program that spans innovative therapies, advances for precise patient selection, and in-depth insights into immune-cancer interactions. Sessions will include focused discussions on Improving Immunity, Tumor Microenvironment, New Targets, and Cellular Therapies. In addition, get novel insights intohow neurons shape the cancer-immune interaction in a dedicated Neuro-Oncoimmunology session. Learn how cutting-edge methodologies enable us to Decode Antigen Recognition and predict immunogenicity.

2025 Confirmed Speakers:

Lunch and Learn Speakers:

Christian Stumpp

Intavis Peptide Services
Germany

Lunch & Learn speaker Christian Stumpp has a M.Sc. in Biochemistry from the University of Tübingen, completed his PhD on protein engineering of interleukins at the TU Dresden and has an MBA focusing on business strategy and marketing from Warwick Business School. He gathered hands-on experience in marketing and sales in several start-ups, scale-ups and in large pharmaceutical corporations like Bayer and AstraZeneca. Since May 2023 he has been building the marketing and business development departments at Intavis Peptide Services.

Christian Stumpp

Intavis Peptide Services
Germany

Lunch & Learn speaker Christian Stumpp has a M.Sc. in Biochemistry from the University of Tübingen, completed his PhD on protein engineering of interleukins at the TU Dresden and has an MBA focusing on business strategy and marketing from Warwick Business School. He gathered hands-on experience in marketing and sales in several start-ups, scale-ups and in large pharmaceutical corporations like Bayer and AstraZeneca. Since May 2023 he has been building the marketing and business development departments at Intavis Peptide Services.

Denise Hartung

Evotec International GmbH
Germany

Bio-Techne supported Lunch & Learn Speaker Denise Hartung finished her graduate studies in the field of “Master of Science Developmental, Neural and Behavioural Biology” at the Georg-August Göttingen in 2020. Shortly after, she joined the drug discovery and development company Evotec as a Research Assistant at the Göttingen site. As part of the Exosome team within the Cell Therapy department, her research focuses on production, purification, QC and functional testing of native and engineered extracellular vesicles (EVs aka exosomes).

Lorenzo Bonaguro

DZNE Bonn
Germany

BD company talk speaker Dr. Lorenzo Bonaguro is a group leader in Molecular and Translational Immunageing at the DZNE Bonn, where he currently leads a research group funded by the ERC StG. He completed his PhD in Molecular Biomedicine at the University of Bonn (2020),with a dissertation on "Creld1 controls T cell homeostasis in mouse and human," under the supervision of Prof. Joachim Schultze and Prof. Michael Hoch. Prior to this, he earned his Master’s in Pharmaceutical Biotechnologies from the University of Padua (2015), focusing on the "Role of Creld1 in Tcell biology," and his Bachelor’s degree in Health Biotechnologies at the same institution (2013). Dr .Bonaguro has worked as Junior Group Leader at ImmunoSensation2, UKB Bonn (2023-2025), and Postdoctoral Fellow in Prof. Joachim Schultze’s lab at the DZNE (2020-2023). He also served as Head of Operations at the PRECISE Genomic Platform at DZNE (2021-2022).

Pascal Bamford

Akoya Biosciences

Pascal Bamford joined Akoya Biosciences in October 2021 in the role of Senior Vice President, Research and Development and Laboratory Operations. He possesses deep scientific and operational experience leading teams in developing and implementing successful and innovative products through international regulatory agencies to customers and patients worldwide. Prior to joining Akoya, he served as Senior Vice President of Products and Services Research and Development at Exact Sciences and has previously held leadership positions at Epic Sciences, Ventana Medical Systems, and Monogen. Pascal earned a PhD in cell image analysis from the University of Queensland, Australia, and a master’s degree in engineering from the University of Bristol, UK, and Ecole Nationale Supérieure des Télécommunications, France.

Subscribe to the CIMT newsletter

Stay up to date on Europe’s largest meeting focused on cancer immunotherapy research and development